Chemotherapy-induced anemia: the story of darbepoetin alfa

Vansteenkiste, Johan; Wauters, Isabelle; Elliott, Steven; Glaspy, John A.; Hedenus, Michael

doi:10.1185/03007995.2013.766593

Cited by 6 publications

(2 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[23] Hence, the fear of adverse impact on overall survival has also been shown to be incorrect by several recent publications. [24][25][26][27][28] Thus, the correct use of ESAs to treat anemia in cancer patients receiving myelosuppressive chemotherapy is appropriate, safe, and beneficial. [29] In order to maximize the benefit for patients, it is recommended to follow published guidelines in general.…”

Section: Discussionmentioning

confidence: 99%

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Biswas

Pandey

Ghadyalpatil

et al. 2020

South Asian J Cancer

View full text Add to dashboard Cite

Introduction: Anemia is a common, underestimated problem in cancer patients receiving myelosuppressive chemotherapy and has significant adverse effect on the quality of life and outcome. Darbepoetin has been shown to be effective in this setting, but controversy surrounds it actual use. Methods: We analyzed prospectively collected clinical practice data of patients receiving darbepoetin in a real-world setting for this retrospective audit. Patients with baseline hemoglobin (Hb) of <11 g/dl were included in this analysis. Their medical records were audited using a predetermined 35-point pro forma. Results: There were a total of 274 patients with advanced cancer receiving myelosuppressive chemotherapy who had baseline Hb <11 g/dl and who were given darbepoetin. Head-and-neck squamous cell carcinoma, lung cancer, and breast cancer were the most common cancers. Their median baseline Hb was 8.9 g/dl which rose to 11.2 g/dl at the end of commenced therapy, along with improved symptomatology. There were no new toxicities, and only two patients required discontinuation of darbepoetin due to toxicity. Conclusion: Darbepoetin is safe and effective in the prevention and management of anemia among patients receiving myelosuppressive chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Biswas

Pandey

Ghadyalpatil

et al. 2020

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“… 6 – 10 The effectiveness of erythropoiesis-stimulating agents (ESAs) and/or red blood cell (RBC) transfusions in managing CIA by raising hemoglobin (Hb) levels is well documented. 11 , 12 However, data on the impact of such treatments on fatigue are more limited.…”

Section: Introductionmentioning

confidence: 99%

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

Mouysset¹,

Freier

Bosch

et al. 2016

CMAR

View full text Add to dashboard Cite

PurposeTo assess hemoglobin (Hb) outcomes and fatigue-related quality-of-life (QoL) (electronic assessment) in patients with solid tumors and symptomatic chemotherapy-induced anemia receiving cytotoxic chemotherapy and darbepoetin alfa (DA) or another erythropoiesis-stimulating agent according to European indication.MethodseAQUA was a Phase IV prospective observational study. The primary outcome (assessed in the primary analysis set [PAS]: patients receiving one or more DA dose who had baseline and week 9 assessments for Hb and QoL) was the proportion of patients receiving DA having both Hb increases ≥1 g/dL and improved QoL between baseline and week 9. Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale scores were anchored to fatigue visual analog scale scores to determine the minimally important difference for improved QoL. Overall data/data over time are reported for the full analysis set (patients receiving one or more erythropoiesis-stimulating agent dose, n=1,158); week 9 data (ie, data relating to the primary and secondary outcomes) are reported for the PAS (n=510). Baseline and safety data are included for both the full analysis set and PAS.ResultsIn the PAS, 69% of patients had stage IV disease and 96% were fatigued. The minimally important difference in FACT-F change score for QoL improvement was 3.5. From baseline to week 9, 32% (95% confidence interval: 28%–36%) of patients had both improved QoL and an Hb increase ≥1 g/dL; proportions were similar across the most common tumor types. At week 9, 49% and 58% of patients had improved QoL or Hb increases ≥1 g/dL, respectively; 70% and 76% had QoL or Hb improvements between baseline and study end, respectively. In the PAS, 16% of patients required transfusions and 32% required iron supplementation. Few patients (<1%) reported adverse drug reactions.ConclusionIn this study, patients with solid tumors receiving DA per European indication for symptomatic chemotherapy-induced anemia had clinically meaningful improvements in Hb and QoL.

show abstract

Characterizing Chemotherapy-Induced Neutropenia and Monocytopenia Through Mathematical Modelling

et al. 2020

View full text Add to dashboard Cite

show abstract

Chemotherapy-induced anemia: the story of darbepoetin alfa

Cited by 6 publications

References 87 publications

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Hemoglobin levels and quality of life in patients with symptomatic chemotherapy-induced anemia: the eAQUA study

Characterizing Chemotherapy-Induced Neutropenia and Monocytopenia Through Mathematical Modelling

Contact Info

Product

Resources

About